跳至主要内容
临床试验/2024-519131-42-02
2024-519131-42-02招募中4 期

F-puff_SE_2024

Semmelweis University1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2025年10月22日最近更新:

试验速览

阶段
4 期
状态
招募中
入组人数
50
试验地点
1
主要终点
responder rate (on NPRS scale)

研究概览

简要总结

Questionary to Fentanyl Nasal Spray Efficiancy and Safety

入排标准

年龄范围
18 years 至 65+ years(65+ Years, 18-64 Years)
接受健康志愿者

入选标准

  • OVER 18 YEARS CANCER PATIENTS UNDER PAIN THERAPY
  • We consider the study to be professionally based only among patients who are treated with F-puff according to the simplified off label recommendation, under routine treatment. Please amend the inclusion criteria with the following: - Patients with severe cancer, where beyond the standard pain relief therapy, severe, acute pain (breakthrough pain) occurs, and who were diagnosed with cancer according to the simplified off label access recommendation by HU NCA (NNGYK) (case number: NNGYK/GYSZ/40594-2/2024).
  • major opioid therapy
  • clear state of mind
  • they can use the nasal spray by themselfes
  • not pregnant, not breastfeeding
  • no cancerous tumour in mouth or nose
  • breath count above 10/min
  • no known fentanyl allergy

排除标准

  • YOUNGER THAN 18 YEARS OLD
  • no malignacy
  • Week lung capacity where assisted respiration is not needed (due to the respiration depressant effect of drugs with morphymomethic nature)
  • Hypersensitivity to fentanyl or to any opioids.

结局指标

主要结局

responder rate (on NPRS scale)

responder rate (on NPRS scale)

次要结局

未报告次要终点

研究者

申办方类型
Educational Institution
责任方
Principal Investigator
主要研究者

Horvath Bohus Anna

Scientific

Semmelweis University

研究点 (1)

Loading locations...

相似试验